The acquisition of brain vascular properties, like tight junctions and pericytes, to form the blood-brain barrier (BBB) is crucial for a properly functioning central nervous system (CNS). Endothelial WNT signaling is a known driver of brain vascular development and BBB properties, however, it is unclear how endothelial WNT signaling is regulated. We recently showed that mouse embryos with disruptions in endothelial retinoic acid (RA) signaling have ectopic WNT signaling in the brain vasculature. Using immunohistochemistical analysis, we show that increased vascular WNT signaling in RA mutants (Pdgfbi cre ; dnRAR403-flox and Rdh10 mutants) is associated with elevated expression of the WNT transcriptional effector, β-catenin, in the brain endothelium. In vitro immunocytochemistry and proximity ligation studies in brain endothelial cells reveal that RA, through its receptor RARα, regulates β-catenin expression in brain endothelial cells via transcriptional suppression and phosphorylation events that targets β-catenin for proteasomal degradation, the latter dependent on PKCα. We find that one function of RA in regulating vascular WNT signaling is to modulate the pericyte numbers in the developing brain vasculature. RA-mediated regulation of vascular WNT signaling could be needed to prevent over-recruitment of pericytes that might impair endothelial-pericyte interactions crucial for vascular stability.
INTRODUCTION
As the central nervous system (CNS) develops, the brain vasculature grows and matures to support proper neural growth and function. The growing brain vasculature made up of endothelial cells quickly obtain unique brain vascular features to support neural growth and function. Important features acquired by the developing brain vasculature include tight junction assembly, expression of transporters, maintaining low-rates of transcytosis and immune invasion, and establishing a high density of pericytes that cover the vasculature. Through these features, the brain blood vessels form the blood-brain barrier (BBB) to limit the infiltration of harmful substances and provide a favorable ionic environment that supports neuronal activity (Hawkins and Davis, 2005; Obermeier et al., 2013; Bauer et al., 2014; Engelhardt and Liebner, 2014) . Recent studies have made strides in our understanding of signals that promote acquisition of these brain vascular features by the developing brain vasculature, however, it is unclear how these signals are regulated to ensure proper acquisition of these properties.
WNT signaling is a major pathway important for growth of the brain vasculature and regulates blood vessel features in the brain, like BBB properties. WNT signaling occurs in brain endothelial cells when neuroepithelial-derived WNT ligands (WNT7a/7b) bind the Frizzled and LRP receptors (LRP5/6) expressed by the brain endothelial cells. This results in the sequestration and silencing of the β-catenin destruction complex (Axin/APC/GSK), consequently halting the proteasomal degradation of β-catenin. β-catenin is then able to translocate to the nucleus and promote the expression of WNT target genes through interactions with TCF/Lef1 (Obermeier et al., 2013) . Along with growth of the brain vasculature, endothelial WNT signaling appears to be important in regulating the acquisition of two main brain vascular features through: (1) The expression of Claudin-5 (Cldn5), a tight junction protein that plays a crucial role in sealing the endothelium and restricting movement of molecules from the blood supply into the neural tissue (Zhou et al., 2014) . (2) The recruitment of pericytes to the brain vasculature that support BBB function (Reis et al., 2012) . Although, endothelial WNT signaling is important for the development of the brain vasculature and acquisition of these brain vascular properties, tight regulation of the WNT signaling pathway appears to be important for vascular stability.
Recently we showed that retinoic acid (RA) functions to regulate WNT signaling and WNT-driven vascular development through two mechanisms: RA balances vascular WNT signaling by (1) acting as a positive regulator of WNT-mediated vascular growth and (2) inhibiting endothelial WNT signaling in a cell autonomous manner. Positive regulation of WNTmediated vascular growth was attributed to RA-mediated suppression of WNT signaling antagonists (Bonney et al., 2016) . However, it is currently unclear how endothelial RA signaling acts to inhibit WNT signaling. The aims of these studies were twofold: (1) to identify the underlying mechanism of how RA cell autonomously inhibits endothelial WNT signaling during brain vascular development. (2) To determine whether RA and WNT signaling work in concert to control the acquisition of WNT-mediated brain vascular properties.
MATERIALS AND METHODS

Animals
Mice used for experiments here were housed in specificpathogen-free facilities approved by AALAC and were handled in accordance with protocols approved by the University of Colorado Anschutz Medical Campus IACUC committee. The following mouse lines were used in this study: PdgfbiCre (Claxton et al., 2008) , dnRAR403-flox (Rosselot et al., 2010) , Ctnnb1-flox (Ctnnb1 LOF ; Brault et al., 2001 ), Ctnnb1-exon3-flox (Ctnnb1 GOF ; Messerschmidt et al., 2016) , Cdh5Cre ERT2 (obtained from Ralf Adams), Sox17-flox (Spence et al., 2009) , and Ai14-flox (Jackson Laboratories, Bar Harbor, ME, United States). The Rdh10 ENU point mutation mice were obtained from Andy Peterson at Genentech (Ashique et al., 2012) . To activate Cremediated recombinase activity, Tamoxifen (Sigma, St. Louis, MO, United States) was dissolved in corn oil (Sigma, St. Louis, MO, United States; 20 mg/ml) and 100 mµl was injected intra-peritoneal into pregnant females at E9.5 and E10.5 to generate PdgfbiCre; Ctnnb1 GOF , PdgfbiCre; dnRAR403-flox, and Cdh5-CreER T2 ;Sox17-flox mutant animals. For generation of PdgfbiCre; Ctnnb1 LOF mutants, tamoxifen was administered to pregnant females on E11.5 and E12.5. For proximity ligation assays, Cdh5cre ERT2/+ ; Ai14 fl/+ pups were used following intraperitoneal injections with 50 µL Tamoxifen (1 µg/mL) at P0 and P1 to express Tdtomato within the vasculature. At P10, mice were anesthetized and transcardiac perfusions were performed with PBS to eliminate background from red blood cells and serum, followed by perfusions and fixation with 4% paraformaldehyde. The skull was removed, the brain was dissected out and then cryoprotected with 20% sucrose in PBS and subsequently frozen in OCT for immunohistochemical processing prior to proximity ligation assays.
Immunohistochemistry
Fetuses (E13.5-E18.5) were collected and whole heads or brains were fixed overnight in 4% paraformaldehyde. All tissues were cryoprotected with 20% sucrose in PBS and subsequently frozen in OCT. Tissue was cryosectioned in 12 µm increments. Immunohistochemistry was performed on tissue sections as described previously (Zarbalis et al., 2007; Siegenthaler et al., 2009) 
Image Analysis
Vascular β-catenin expression was determined in E13.5 Wildtype (Rdh10 +/+ and Rdh10 +/− ; n = 6 animals) and Rdh10 mutants (Rdh10 −/− ; n = 5 animals). Similarly, vascular β-catenin and Claudin-5 expression was determined in E18.5 dnRAR fl/fl (n = 6 animals), and Pdgfbi cre/+ ; dnRAR403 fl/fl animals (n = 5 animals). To quantify the percent of vascular β-catenin or Claudin-5 expression within the vasculature the length (nm) of β-catenin and Claudin-5 expression was measured and normalized to the total length of Ib4 + blood vessels (nm) per immunofluorescent confocal image using Zen software. Pericyte coverage was determined in brains of: E13.5 Wildtype (Rdh10 +/+ and Rdh10 +/− ; n = 6 animals) and Rdh10 mutants (Rdh10 −/− ; n = 5 animals); E18.5 dnRAR fl/fl (n = 6 animals), and Pdgfbi cre/+ ; dnRAR403 fl/fl (n = 5 animals); E14.5 Ctnnb1 GOF/+ (n = 4 animals) and Pdgfbi cre/+ ; Ctnnb1 GOF/+ (n = 4 animals); Pdgfbi cre/+ ; E14.5 Ctnnb1 LOF/+ (n = 3 animals) and Pdgfbi cre/+ ; Ctnnb1 LOF/LOF (n = 3 animals); E14.5 Sox17 fl/fl (n = 6 animals) and Cdh5 CreERT2/+ ; Sox17 fl/fl (n = 6 animals). To quantify pericyte coverage the number of Pdgfrβ/CoupTFII + cells surrounding the Ib4 + vasculature was counted. Pdgfrβ localizes to the membrane of pericytes while CoupTFII labels pericyte nuclei (along with some neuronal nuclei and venous endothelial cells), thus a pericyte was counted if it was both Pdgfrβ and CoupTFII positive and surrounding the Ib4 labeled vasculature. The number of pericytes were quantified using this method and divided by the total length of Ib4 + blood vessels (µm) and then multiplied by 100 to achieve number of pericytes per 100 µm of blood vessels. All analysis was performed using Zen software on 3-5 20x images per brain/animal. Analysis on the Pdgfbi cre/+ ; dnRAR403-flox experiments were blinded. Analysis on the PdgfbiCre; Ctnnb1 GOF animals were not blinded. Due to obvious vascular defects, analysis on PdgfbiCre; Ctnnb1 LOF , Rdh10, and Cdh5-CreER T2 ;Sox17-flox animals were not blinded.
Whole Brain Transcriptional Analysis
Meninges were removed from the brains of Cdh5 creERT2 ; Sox17 fl/fl (E14.5; n = 11 animals), and Sox17 fl/fl (E14.5; n = 6 animals). RNA was isolated from whole brains with Qiagen RNAeasy (Hilden, Germany). cDNA was then synthesized using iScript cDNA synthesis kit (BioRad, Hercules, CA, United States) and qRT-PCR was performed to analyze WNT signaling (Axin2 and Lef1), Pdgfb, and Pdgfrβ. Actb transcript levels were also assessed and used to normalize expression levels. Delta-delta Ct analysis was performed and fold change over control is reported. Actb forward: CTAGGCACCAG GGTGTGAT, Actb reverse: TGCCAGATCTTCTCCAT GTC; Axin2 forward: GTGCCGACCTCAAGTGCAA, Axin2 reverse: GGTGGCCCGAAGAGTTTTG; Lef1 forward: AGG GCGACTTAGCCGACAT, Lef1 reverse: GGGCTTGTCTGAC CACCTCAT; Pdgfb forward: GGAGTCGAGTTGGAAAG CTCA, Pdgfb reverse: ACCAGGAAGTTGGCGTTGGT; Pdgfrβ forward: CTGTGAATGCCGTGCAGACT, Pdgfrβ reverse: TGGAAGTTCACCACATCATTGC.
bEnd.3 Cell Line and Treatments
The mouse brain endothelioma cell line (bEnd.3) was obtained from ATCC (Manassas, VA, United States; cat# CRL-2299). All experiments were performed on cells from passages 2-15 and cells were grown in Dulbecco's minimal essential media with 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, 4 µm L-glutamine (Invitrogen, Carlsbad, CA, United States), 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, United States) and Penicillin mRNA Analysis in bEnd.3 Cells Ctnnb1 expression was analyzed in the bEnd.3 cells following 24hr vehicle or RA exposure +/− RARi. Cells were then lysed with RLT buffer, RNA was isolated, cDNA was generated, and Ctnnb1 expression was assessed by qRT-PCR and normalized to Actb expression. Delta-delta Ct analysis was performed and fold change over vehicle control is reported. Each independent experiment (n = 3) was performed on 3 separate passages with at least 3 samples per treatment condition (technical replicates). Ctnnb1 forward: GGTGGGCTGGTATCTCAGAA, Ctnnb1 reverse: CAAGCAAGGCTAGGGTTTGA.
Immunocytochemistry in bEnd.3 Cells
Immunocytochemistry (ICC) experiments were performed on bEnd.3 cells plated on collagen-coated chambered slides (Thermo Fisher Scientific, Waltham, MA, United States). For experiments analyzing phospho-β-catenin expression or PKC activity (p-PKC substrate) bEnd.3 cells were treated for 24 h with vehicle or RA +/− RARi or +/− PKCi. For experiments analyzing total β-catenin expression bEnd.3 cells were treated for 48 h with vehicle or RA +/− RARi, +/− PKCi, or +/− Proteasomeinh. Following treatments, cells then were fixed with 100% methanol for 10 min and incubated with mouse anti-β-catenin antibody (1:100; Cell Signaling, Danvers, MA, United States), rabbit anti-phospho-β-catenin (1:100; Cell signaling, Danvers, MA, United States), or rabbit anti-phospho-PKC substrate (1:100; Cell Signaling, Danvers, MA, United States) for 1 h at room temperature. Cells were then incubated the appropriate AlexaFluor secondary and immunofluorescent images were captured using a Zeiss (Thornwood, NY, United States) 780 LSM confocal microscope. For fluorescent intensity quantification, images were analyzed using Zen imaging software and β-catenin, p-bcatenin, or p-PKCsub fluorescent intensity was normalized to total number of DAPI + cells per 20x image. Each independent experiment (n = 3) was performed on 3 separate passages with 3-5 images captured and analyzed per treatment condition. Due to laser power and gain settings needing to be consistent between vehicle and treated samples to accurately analyze expression of protein of interest, imaging and analysis was not blinded.
Proximity Ligation Assays in bEnd.3 Cells and Tissue
Proximity ligation assays (PLAs) were performed on bEnd.3 cells plated on collagen-coated chambered slides (Thermo Fisher Scientific, Waltham, MA, United States) following 0, 2, 4, and 8 h of treatment with RA. Cells were fixed for 10mins with 100% methanol and PLA assays were performed according to Duolink PLA protocol specifics (Sigma, St. Louis, MO, United States). To detect potential protein-protein interactions, samples were co-incubated for 1hr at room temperature with the following antibodies: β-catenin-RARα: mouse anti-β-catenin (1:100; Cell Signaling, Danvers, MA, United States) and rabbit anti-RARα (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, United States); β-catenin-PKCα: mouse anti-β-catenin (1:100; Cell Signaling, Danvers, MA, United States) and rabbit anti-PKCα (1:100; Cell Signaling, Danvers, MA, United States); RARα-PKCα: goat anti-RARα (1:100; Abcam, Cambridge, MA, United States) and rabbit anti-PKCα (1:100; Cell signaling, Danvers, MA, United States); β-catenin-VE-cadherin (positive control): mouse anti-β-catenin (1:100; Cell signaling, Danvers, MA, United States) and rabbit VE-cadherin (1:200; Abcam, Cambridge, MA, United States); ZO-1-RARα (negative control): mouse anti-ZO-1 (1:100; Thermo Fisher Scientific, Waltham, MA, United States) and rabbit anti-RARα (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, United States). Following confocal imaging, analysis of PLA puncta was performed using ImageJ and threshold, particle analysis. Number of puncta were normalized to total number of DAPI + bEnd.3 cells to get the number of puncta/cell. The number of ZO-1-RARα puncta/cell (on average ∼0.17 puncta/cell) were determined in all conditions and subtracted as background from all proteinprotein interaction analyses. Because imaging settings (laser power and gain) had to be set to positive controls and positive PLA staining, experiments were not blinded. PLA experiments were also performed on perfused PFA-fixed brain sections (no antigen retrieval) from postnatal day 10 Cdh5cre ERT2/+ ; Ai14 fl/+ to detect these protein-protein interactions within the Tdtomato-expressing vasculature, however, antibody incubations were performed overnight at 4
• C. Immunofluorescent images were captured using a Zeiss (Thornwood, NY, United States) 780 LSM confocal microscope where laser power and gain settings were set the same between experimental, positive and negative control samples.
Microvessel Isolation, Multi-Gene Transcriptional Profiling
Microvessels were isolated from E18.5 (n = 3 animals) Pdgfbi cre/+ ;Ctnnb1 LOF/LOF and Pdgfbi cre/+ ;Ctnnb1 LOF/+ brains using PECAM/CD31-coated magnetic beads as previously described (Siegenthaler et al., 2013) . RNA was isolated, cDNA was generated, and multigene transcriptional profiling, a form of quantitative RT-PCR, was used to determine the number of mRNA copies per cell normalized to 18S rRNA abundance (10 6 18S-rRNA copies/cell) (Shih and Smith, 2005) . For each sample, mRNA copy numbers for Lef1, Axin2, Sox17, Pdgfb, and Pdgfrβ were normalized to CD144 copy number to correct for variability in microvessel isolation between brains. Cd144 forward: CAACTTCACCCTCATAAACA ACCAT, Cd144 reverse: ACTTGGCATGCTCCCGATT; Sox17 forward: GGCCGATGAACGCCTTTAT, Sox17 reverse: AGCT CTGCGTTGTGCAGATCT.
Sox17 Knock-Down Experiments and Chromatin-Immunoprecipitation in bEnd.3 Cells
For Sox17 knock-down experiments, cells were plated on 24-well plates and allowed to grow to ∼70% confluency prior to siRNA transfection with non-targeting control (Scrambled) and mouse Sox17-targeting siRNA (SMARTpool; Dharmacon, Lafayette, CO, United States). siRNA transfection was performed using Dharmefect 4 and according to Dharmacon siRNA transfection specifications. Expression levels of Sox17 and Pdgfb from four independent experiments (n = 4) were analyzed via qRT-PCR after 48 h of transfection. Chromatinimmunoprecipitation (ChIP) assays for Sox17 were performed using the SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling, Danvers, MA, United States). Specifically the bEnd.3 cells were grown on 5-15cm until they reached ∼80-90% confluency and then fixed with 1.5% EM-grade formaldehyde for 20 min (Polysciences Inc., Warrington, PA, United States). After stopping the fixation process, the DNA was digested with 1,000 gel units of nuclease for 10 min at 37 • C. The nuclei were then sonicated 5 × 10 s at 100% power and then incubated on ice for 30 min to ensure efficient lysis of the nuclei. ChIP was performed at 4 • C overnight on 10 mg of DNA with 10 µg of antibodies against α-Sox17 (n = 4 independent experiments; R&D Systems, Minneapolis, MN, United States), α-HistoneH3 (n = 2 independent experiments; Cell Signaling, Danvers, MA, United States), and α-Rabbit IgG (n = 2 independent experiments; Cell Signaling, Danvers, MA, United States). Once eluted, the ChIP-DNA and input were incubated with proteinase K overnight at 65 • C. After DNA purification, qRT-PCR was performed for 8 potential Sox17 binding sites up-stream and within the Pdgfb locus were probed for using SsoAdvanced Sybr Green (BioRad, Hercules, CA, United States). Potential consensus binding sites were identified using biogrid-lasagna which identified variations of the Sox17 binding sequence 
Statistics
To detect statistically significant differences in mean values of control and mutant genotypes at one developmental time point (vascular β-catenin or Claudin-5 expression, pericyte density, qPCR analysis), Student t tests were used. For analysis that compared more than two groups (e.g., multiple treatment conditions, timepoints) we used a one-way analysis of variance (ANOVA) with Tukey's post hoc analysis was used to detect statistically significant differences between treatment conditions or timepoints. P-values less than 0.05 were considered statistically significant in these studies with specific p-values reported on all graphs. The standard deviation (SD) is reported on all graphs.
RESULTS
Retinoic Acid Regulates β-catenin Expression in Brain Endothelial Cells
Our previous work showed that RA cell autonomously regulates endothelial WNT signaling in the developing brain vasculature (Bonney et al., 2016) . Other work in various cell types have suggested that RA is capable of reducing the expression of the WNT transcriptional effector, β-catenin (Lim et al., 2012; Zhu et al., 2015; Zito et al., 2017) . Therefore, it is possible that RA regulates β-catenin expression to modulate endothelial WNT signaling. Thus we investigated the protein expression of β-catenin in the brain vasculature of mouse mutants that have an ENU point mutation in the RA synthesizing enzyme, Rdh10, resulting in an embryo-wide reduction of RA and RA signaling (Ashique et al., 2012) . The RA-mediated inhibition of endothelial WNT signaling was observed within the nonneocortical vasculature of Rdh10 mutants (Bonney et al., 2016) . We therefore analyzed expression of β-catenin in the nonneocortical vasculature at E13.5 (this mutation in Rdh10 results in embryonic lethality by E14.5). Surprisingly we found a significant increase in the expression of β-catenin within the non-neocortical (thalamus) vasculature of Rdh10 mutants ( Figures 1A,B,B') . We also observed a potential increased expression of neural β-catenin, potentially due to the embryo-wide reduction in RA synthesis and signaling ( Figure 1B) .
We next took an endothelial-specific approach by disrupting RA signaling within the developing vasculature. To do this we expressed a dominant-negative retinoic-acid receptor (RAR) allele, dnRAR403, in the developing vasculature using the endothelial-specific Cre recombinase Pdgbi cre (Pdgfb-CreER T2 ) where expression of dnRAR403 essentially silences endogenous RA-RAR signaling (Tsai et al., 1992; Damm et al., 1993; Lohnes et al., 1994) . Expression of dnRAR403 in the vasculature does not alter survival of the embryos and thus permits later analysis of a more mature brain vasculature than the Rdh10 mutants. Like the non-neocortical vasculature of Rdh10 mutants, we also showed previously that Pdgfbi cre/+ ; dnRAR403 fl/fl embryos have elevated endothelial WNT signaling in the developing neocortical brain vasculature (Bonney et al., 2016) . Associated with this, we found a significant elevation in β-catenin expression in the neocortical brain vasculature of Pdgfbi cre ; dnRAR403 fl/fl embryos when compared to dnRAR403 fl/fl controls ( Figures 1C,C') . We next tested the sufficiency of RA to suppress β-catenin protein expression using bEnd.3 cells, a brain endothelioma cell line. Immunocytochemical analysis of β-catenin in bEnd.3 cells showed reduced expression after 48 h of 50 nM all-trans RA (hereafter referred to as RA) treatment, a concentration we previously showed inhibits WNT signaling (Figures 1D,D') . The RA-mediated suppression of β-catenin protein expression in the bEnd.3 cells was blocked with the addition of a pan RAR inhibitor, AGN 194310 (Figures 1D,D') . Of note, due to lack of WNT ligand exposure in these experiments, β-catenin localizes to the adheren junctions and not the nucleus. Together, this indicates that RA is sufficient to control β-catenin expression in brain endothelial cells and this depends on RAR activity.
We next investigated if RA is capable of regulating β-catenin transcriptionally or via proteasomal degradation. Transcriptional expression of Ctnnb1 was significantly reduced following 24 h of RA exposure and this effect was blocked with the addition of the pan RAR inhibitor (Figure 2A) . We further found that treatment with a proteasome inhibitor, MG-132, blocked the RA-mediated reduction in β-catenin protein expression ( Figures 2B,B' ). From this data we conclude that RA reduces β-catenin expression at the transcriptional level and via a mechanism that involves proteasomal degradation.
Retinoic Acid Induces the Phosphorylation of β-catenin Through RAR and PKC Activity
We undertook experiments to understand how RA may regulate the proteasomal-mediated degradation of β-catenin. We began by investigating whether RA promotes the phosphorylation of β-catenin at Ser33, Ser37 and Thr41, which generally marks β-catenin for proteasomal degradation (Verheyen and Gottardi, 2010) . Following 24 h of RA exposure in the bEnd.3 cells, we saw an increase in the phosphorylation of β-catenin (Ser33/Ser37/Thr41) and this required RAR activity ( Figures 3A,A') . RA has been shown to activate a number of kinases such as PKC (del Rincon et al., 2004; Miloso et al., 2004; Aggarwal et al., 2006) and PKC can phosphorylate β-catenin at Ser33/Ser37 and target it for degradation (Gwak et al., 2006) . We next tested if the RA-mediated phosphorylation of β-catenin protein requires PKC by exposing bEnd.3 cells to a PKC inhibitor, bisindoylmaleimide I (BIM), with and without RA. Inhibiting PKC activity blocked the RA-mediated phosphorylation of β-catenin ( Figures 3A,A') . Furthermore, RA treatment activated PKC activity as shown by an increase in the phosphorylation of PKC substrates ( Figures 3B,B' ). Treatment with BIM effectively reduced PKC phosphorylation activity with and without RA ( Figures 3B,B') . Interestingly, treatment with the RAR inhibitor in the presence of RA also attenuated PKC phosphorylation activity ( Figures 3B,B' ) suggesting that RA requires RAR activity to activate PKC. The reduction in total β-catenin expression mediated by RA was blocked with addition of BIM ( Figures 3C,C' ). Together, this data suggests that RA activates PKC activity through RARs and this results in phosphorylation and the eventual degradation of β-catenin.
Retinoic Acid Induces Interactions Between β-catenin With RARα and PKCα
Given the robust effect of RA on promoting β-catenin phosphorylation and protein degradation, we next investigated how RA may be functioning to phosphorylate β-catenin. RARα, which is highly expressed by the developing brain vasculature in mice (Bonney et al., 2016) , has been shown to directly interact with β-catenin (Easwaran et al., 1999; Chanda et al., 2013) . Possibly, RA treatment induces a complex formation between RARα, β-catenin, and PKC to target β-catenin for degradation via phosphorylation. To test this we performed proximity ligation assays (PLAs) which allowed us to assess if RARα, β-catenin and PKCα are within close proximity (∼40 nm) to one another, suggestive of complex formation.
Following 2 h of RA exposure, we found a substantial increase in β-catenin-RARα PLA puncta, indicating that RARα and β-catenin were within close proximity to one another. The puncta were generally found within the cytoplasm and were sustained after 8 h of RA exposure ( Figures 4A,A') . After 4 h of RA exposure we found a significant increase in β-catenin-PKCα puncta suggesting RA facilitates interactions between β-catenin and PKCα ( Figures 4B,B' ). Similar observations were noted in PLAs performed for RARα and PKCα after 4 h of RA exposure, however, it appears that RARα and PKCα may interact at baseline conditions, without the presence of RA ( Figures 4C,C' ). This suggests that under normal conditions RARα interacts with PKCα and in the presence of RA, RARα is then activated and binds to β-catenin where it then facilitates interactions between β-catenin and PKCα. These interactions could then allow for the phosphorylation events that target β-catenin for degradation. We found a significant reduction in PLA puncta for β-catenin-VE-cadherin following 24 h of RA exposure ( Figures 4D,D' ) suggesting that RA is capable of reducing β-catenin destined for or bound at the adheren junctions. Importantly, very few PLA puncta were observed in our negative control (RARα-ZO-1; Figure 4E ). Collectively, our in vitro data suggests a model where in the presence of RA, RARα can (1) transcriptionally suppress Ctnnb1 expression and (2) bind β-catenin and target it for degradation through phosphorylations via interactions with PKCα ( Figure 4F ). We next looked for indication of these interactions in the brain vasculature. Due to high background from serum and red blood cell contamination in embryonic tissue, PLA experiments were performed on perfused postnatal (P10) Cdh5creERT2/+; Ai14fl/+ tissue that had Tdtomato expression in the endothelium. We observed positive PLA staining for β-catenin-RARα within the Tdtomato-expressing vasculature (arrows; Figure 4G ). We also noted puncta indicative of interactions between β-catenin and RARα in other cells within the brain (closed arrows; Figure 4G ). Additionally, we found positive PLA interactions between β-catenin-PKCα, RARα-PKCα, and β-catenin-VE-cadherin (positive control) which appeared mostly within the Tdtomato-expressing vasculature (arrows; Figure 4G) . A faint signal was detected in the negative control (RARα-ZO1) in the Tdtomato-expressing vasculature, however, this was at a much lower intensity than the other PLA interactions (arrows; Figure 4G ). From these investigations, we conclude that RA regulates β-catenin expression in part through proteasomal degradation and this involves RA-mediated interactions between RARα, β-catenin and PKCα in the brain endothelium.
Ectopic Vascular WNT-β-catenin Signaling in RA Mutants Result in Increased Pericytes Along the Developing Brain Vasculature
We next tested if RA inhibition of endothelial WNT signaling has any role in modulating WNT-driven brain vascular properties, like BBB formation. Ectopic WNT signaling in the developing vasculature of Rdh10 and Pdgfbi cre ; dnRAR403 fl/fl mutants (Bonney et al., 2016) could result in increased expression of the TJ protein and WNT-target, Cldn5, and impair BBB function. Our previous work addressing the role of RA in BBB development showed that Rdh10 mutants do not have alterations in vascular protein expression of Cldn5 or overt leakage of fibrinogen by the brain vasculature (Bonney and Siegenthaler, 2017) . Further, disrupting vascular RA signaling (Pdgfbi cre ; dnRAR403 fl/fl ) did not result in up-regulation of Cldn5 in the vasculature (Supplementary Figures 1A,A') . Additionally, leakage of fibrinogen was not observed suggesting BBB function is normal in these animals (Supplementary Figure 1B) . This suggests that endothelial RA does not function upstream of WNT-β-catenin signaling to modulate TJ protein expression.
In addition to TJ formation, WNT signaling may play a role in the recruitment of pericytes to the brain vasculature through regulation of pericyte mitogen and chemoattractant PDGF-B (Reis et al., 2012) . We next tested if the increase in WNT-β-catenin signaling we observe in our RA signaling/synthesis mouse mutants (Bonney et al., 2016) increases pericyte numbers in developing brain vasculature. Indeed, we observed a significant increase in the number of Pdgfrβ + pericytes covering the vasculature in Rdh10 mutants (thalamus E13.5; Figures 5A,A' ) and in Pdgfbi cre/+ ; dnRAR403 fl/fl embryos (cortex E17.5; Figures 5B,B' ) when compared to controls. We next tested if ectopic WNT-β-catenin signaling is sufficient to increase pericyte numbers through a WNT gain-of-function approach by utilizing the Ctnnb1-exon3-flox (Ctnnb1 GOF ) mice crossed with Pdgfbi cre mice. Over-activation of WNT-β-catenin signaling in the embryonic brain vasculature (E14.5; Pdgfbi cre/+ ; Ctnnb1 GOF/+ ) significantly increased pericyte numbers ( Figures 5C,C' ). Our analysis suggests that ectopic vascular WNT signaling and β-catenin expression in the Rdh10 and Pdgfbi cre/+; dnRAR403 fl/fl mutants results in elevated pericyte numbers in the developing brain vasculature. Thus, appropriate brain pericyte recruitment may be an important function of RA in modulating endothelial WNT-β-catenin signaling.
Vascular WNT Signaling and Sox17 Regulate Pericyte Numbers Along the Developing Brain Vasculature
Our studies using the Pdgfbi Cre/+ : Ctnnb1 GOF/+ (Figure 5 ) and studies of pathological brain tumor vasculature demonstrate that increasing endothelial WNT-β-catenin signaling is sufficient to promote pericyte recruitment to the vasculature via PDGF-B (Reis et al., 2012) . It is not known, however, if WNT-β-catenin is required for the high pericyte density in the developing brain vasculature. We tested this by conditionally knocking out β-catenin in the endothelium using the Pdgfbi cre/+ ; FIGURE 5 | Ectopic vascular WNT signaling in RA mutants result in increased pericytes along the developing brain vasculature. (A-C) Immunohistochemical (IHC) images of the (A) thalamic regions from E13.5 Wild-type (Rdh10 +/+ or Rdh10 +/-) and Rdh10 (Rdh10 -/-), (B) cortical plate from E18.5 dnRAR403 fl/fl and Pdgfbi Cre/+ ; dnRAR403 fl/fl , and (C) cortical plate from E14.5 Ctnnb1 GOF/+ and Pdgfbi cre/+ ; Ctnnb1 GOF/+ brains stained for Pdgfrβ (green) and blue) . Enlarged images and arrows indicate Pdgfrβ + pericytes surrounding the Ib4 + vasculature. (A-C') Quantification and analyses (Student's t-test) for the number of pericytes co-labeled for Pdgfrβ and CoupTFII (staining not shown)/100 µm of Ib4 + blood vessels from (A') Wild-type (gray; n = 5 animals) and Rdh10 mutants (black; n = 5 animals), (B') dnRAR403 fl/fl (gray; n = 6 animals) and Pdgfbi Cre/+ ; dnRAR403 fl/fl (black; n = 6 animals), and (C') Ctnnb1 GOF/+ (gray; n = 4 animals) and Pdgfbi cre/+ ; Ctnnb1 GOF/+ (black; n = 4 animals). Scale bars are 50 µm. Ctnnb1 LOF/LOF animals. Compared to controls (Pdgfbi cre/+ ; Ctnnb1 LOF/+ ), we found that Pdgfbi cre/+ ; Ctnnb1 LOF/LOF resulted in a significant reduction in number of pericytes along the vasculature (Figures 6A,A' ). This correlated with a significant reduction in the expression of Pdgfb along with the WNT target genes (Lef1, Axin2, and Sox17) in brain microvessels isolated from Pdgfbi cre/+ ; Ctnnb1 LOF/LOF E14.5 embryos. We also detected a significant reduction in Pdgfrβ since the Pdgfrβ-expressing pericytes are included in the microvessel isolations, further supporting a reduction in pericyte numbers ( Figure 6B) .
We next investigated how WNT-β-catenin signaling might regulate brain pericyte density. Direct regulation of the pericyte mitogen gene, Pdgfb, by the WNT transcriptional machinery, TCF/Lef1, seemed unlikely since we were unable to find TCF/Lef1 binding site motifs in or near the Pdgfb locus using the LASANGA transcription factor binding site search engine. Sox17, a transcription factor downstream of WNT signaling, has been shown to regulate mural cell coverage in the developing retinal vasculature (Corada et al., 2013) . Our work and others have shown that WNT signaling is a major regulator of Sox17 during vascular development and disrupting endothelial RA signaling results in ectopic Sox17 expression in the brain vasculature (Ye et al., 2009; Corada et al., 2013; Bonney et al., 2016) . We therefore assessed the role of Sox17 in regulating pericyte numbers by deleting Sox17 in the vasculature of embryos (Cdh5 creERT2 ; Sox17 fl/fl ). We found that deletion of Sox17 in the endothelium (Cdh5 creERT2 ; Sox17 fl/fl vs. Sox17 fl/fl embryos) resulted in reduced numbers of pericytes in the E14.5 brain vasculature ( Figures 6C,C') . We also found a significant reduction in Pdgfb, Pdgfrβ, and Axin2 expression in whole brains of E14.5 Cdh5 creERT2 ;Sox17 fl/fl embryos when compared to Sox17 fl/fl controls. Lef1 expression was not significantly affected by loss of Sox17 in the brain vasculature ( Figure 6D ). This suggests that Sox17 regulates pericyte numbers and Pdgfb expression during brain vascular development downstream of endothelial WNT signaling.
We next tested if Sox17 might be a direct transcriptional regulator of Pdgfb expression in brain endothelial cells. Knockdown of Sox17 in the bEnd.3 cells using siRNA resulted in a significant reduction in Sox17 and Pdgfb expression when compared to Scrambled siRNA treated (Scr) control cultures ( Figure 6E) . We next analyzed the Pdgfb locus for Sox17 binding sites where we identified eight variations of the Sox17 consensus binding sites ranging from − 3778 bps upstream of the transcriptional start site to + 822 bps within the first exon. Chromatin Immunoprecipitation-qPCR assays (ChIP-qPCR) for Sox17 in the bEnd.3 cells showed an enrichment of Sox17 at − 1445-1436 bps and + 805-822 bps binding sites ( Figure 6F) . Positive control ChIP-qPCRs for histone H3 had a high percent of input while we found a low percent of input for the negative control (α-rat IgG) at all eight binding sites indicating the ChIPqPCRs were successful and non-specific binding was minimal (Figure 6F ). This data indicates that Pdgfb is potentially a direct transcriptional target of Sox17 in the brain endothelium.
DISCUSSION
Our findings extend our previous work by identifying a mechanism by which RA regulates brain endothelial WNT-β-catenin signaling ( Figure 7A) . Further, our work suggests regulation of PDGF-B expression and brain pericytes via Sox17 as another potential facet of WNT-β-catenin regulation of BBB properties and a target of RA inhibition ( Figure 7A) .
Our work provides two mechanisms for how RA controls WNT-β-catenin signaling, a modulatory role for RA that may be important for regulating pericytes during brain vascular development. First, we show that RA mutants (Rdh10 and Pdgfbi cre ; dnRAR403 fl/fl mutants) have enhanced vascular β-catenin expression. We believe this is in part due to loss of RA-mediated suppression of Ctnnb1 in brain endothelial cells. A similar mechanism was recently described in H-1975 cells (a human adenocarcinoma cell line) where RA promotes the activity of GATA6, a transcriptional repressor, to downregulate Ctnnb1 expression (Zito et al., 2017) . Second, we show that RA has a separate, non-nuclear function, that promotes the phosphorylation and proteasome-mediated degradation of β-catenin in brain endothelial cells via its receptor RARα and PKC activity. RA-RARα regulation of signaling pathways, independent of transcriptional activity, is well-documented. RA-RAR has been shown to regulate ERK signaling (Miloso et al., 2004) , insulin-receptor substrate-1 signaling (del Rincon et al., 2004) , and CREB activity (Aggarwal et al., 2006) . In the brain specifically, membrane associated RARα in hippocampal neurons regulates local translation of mRNA in dendrites and induces new spine formation (Chen and Napoli, 2008; Maghsoodi et al., 2008) . Our time course experiments using PLAs indicate that RA-mediated degradation of β-catenin is a faster and, possibly, the more robust mechanism by which RA modulates WNT signaling, especially given the swift interactions (2-4hrs post RA exposure) between RARα, β-catenin and PKCα. Interestingly, RARα appears to interact with PKCα prior to RA stimulus, however, interactions are heightened following RA treatment (4 h). These data support a model in which RARα sits in a complex with PKCα and upon RA stimulation, RARα binds β-catenin and facilitates interactions between β-catenin and PKCα. This leads to the PKC-and RAR-mediated phosphorylation of β-catenin that target it for proteasomal degradation. Interestingly, the reductions in β-catenin and VEcadherin interactions we observed following RA exposure suggest that RA is capable of degrading β-catenin destined for and/or located at the adherens junctions. Most importantly, we show the interactions between β-catenin with RARα and PKCα are present in the brain vasculature in vivo.
In an effort to understand the significance of RA-mediated regulation of endothelial WNT signaling, we investigated WNT-β-catenin regulated BBB properties. Based on data from our mouse mutants with enhanced vascular β-catenin expression and WNT-β-catenin signaling (Rdh10 and Pdgfbi cre ; dnRAR403 fl/fl mutants), it is unlikely RA plays a role in regulating the TJ protein Cldn5, a known target of WNT-β-catenin (Rdh10 mutants; Bonney and Siegenthaler, 2017) . We also did not observe overt leakage of fibrinogen indicating that the barrier is intact in the absence of normal RA levels or signaling. Pericyte numbers, however, were increased in the developing brain vasculature suggesting that endothelial RA signaling, functioning upstream of WNT-β-catenin signaling, is involved in regulating pericyte density in the brain vasculature. Pdgfbi cre/+ ; dnRAR403 fl/fl embryos have vascular dysplasia and, in some cases, brain microhemorrhages (Bonney et al., 2016) . This suggests that despite the importance of pericytes in the brain, increasing their numbers might impair vascular stability. Possibly, this could be due to enhanced PDGF-B-PDGFrβ signaling causing disruptions in normal pericyte-endothelial cell interactions or crosstalk that is needed for vascular integrity. In support of this, recent investigations in a mouse model of retinopathy showed over-activation of PDGF-B/Pdgfrβ signaling results in excessive pericyte coverage in the retina and promotes the formation of neovascular tufts, which are indicative of endothelial cell over-proliferation. This results in a leaky vascular network that is weak and prone to hemorrhage (Dubrac et al., 2018) . Further, expression of a constitutively active form of Pdgfrβ results in impaired brain pericyte differentiation and significantly increased brain capillary diameter (Olson and Soriano, 2011) .
Endothelial WNT signaling is uniquely required for brain angiogenesis and establishment of the BBB (Liebner et al., 2008; Stenman et al., 2008; Daneman et al., 2009; Zhou et al., 2014) however, the downstream targets of WNT-β-catenin that mediate its effects on vascular growth and BBB properties are incompletely understood. Endothelial WNT-β-catenin has been previously shown to be sufficient to induce PDGF-B expression and enhance pericyte coverage in brain tumors (Reis et al., 2012) however, to our knowledge, our studies using Pdgfbi Cre ; Ctnnb1 LOF and Pdgfbi Cre ; Ctnnb1 GOF mutants are the first to look at this in the developing brain vasculature. The reduction in pericyte number and Pdgfb expression in Pdgfbi Cre ; Ctnnb1 LOF indicate endothelial WNT-β-catenin may be needed to help establish the high number of brain pericytes required for brain vasculature development and maturation. In support of this, comparative endothelial translatome analysis showed Pdgfb as well as WNT-β-catenin signaling genes were significantly higher in brain endothelial cells as compared to endothelial cells from whole head, limb, heart, liver, kidney, and lung at E14.5 (Hupe et al., 2017) . Based on our data presented here and work by others (Corada et al., 2013; Lee et al., 2015) , Sox17 acts downstream of WNT-β-catenin to regulate endothelial Pdgfb and pericyte numbers. Moreover, our in vitro experiments suggest that Sox17 directly regulates Pdgfb expression by binding to the Pdgfb locus and promoting its transcription in brain endothelial cells. It is important to note that that deletion of β-catenin or Sox17 in the endothelium results in a fewer brain pericytes, a much milder phenotype than the almost complete lack of brain pericytes observed in Pdgfb and Pdgfrβ knockout mice. This indicates other pathways regulate endothelial PDGF-B and pericyte recruitment in the CNS, likely the same pathways that control PDGF-B in all developing vascular networks. Further, our studies do not address if alterations in the initial recruitment, proliferation or cell death underlie elevated or reduced pericyte numbers in the various mutants. PDGF-B-PDGFrβ signaling is a mitogen, chemoattractant and pro-survival factor for pericytes, suggesting that changes in multiple cellular processes may underlie altered pericyte number in these mutants.
In summary, our model is that, on the one hand, endothelial WNT-Sox17 may provide the additional stimulus of PDGF-B ligand needed to establish high numbers of pericytes that is unique to the CNS vasculature. On the other side, RA balances out WNT-β-catenin signaling and, potentially, PDGF-B expression through Sox17. With the appropriate PDGF-B-PDGFrβ signaling level set by these pathway components, pericytes are able to 'settle' in the vasculature and form interactions with and secrete factors onto brain endothelial cells required for vessel stability ( Figure 7B ).
AUTHOR CONTRIBUTIONS
SB and JS designed the research. SB, BD, MW, and JS performed the experiments and acquired the data. SB, BD, and JS analyzed the data. SB and JS wrote and edited the manuscript.
FUNDING
This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (K99-R00 NS070920 and R01 NS098273 to JS, F31 NS100565 to SB) and Children's Hospital Colorado Research Institute (startup funds to JS).
